Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic strains: An epidemiological model

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yakob, Laith ^a   Riley, Thomas V ^b   Paterson, David L ^c   Marquess, John ^d   Magalhaes, Ricardo J Soares ^e   Furuya Kanamori, Luis ^f   Clements, Archie C A ^f  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d QUEENSLAND HEALTH   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CLASSIFICATION; ENDEMIC DISEASE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EUROPE; GENETICS; HUMAN; MARKOV CHAIN; MICROBIOLOGY; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; RIBOTYPING; SPECIES DIFFERENCE; THEORETICAL MODEL; TRANSMISSION; VIRULENCE;

ALGORITHMS; CLOSTRIDIUM DIFFICILE; ENDEMIC DISEASES; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EUROPE; HUMANS; MODELS, THEORETICAL; RIBOTYPING; SPECIES SPECIFICITY; STOCHASTIC PROCESSES; VIRULENCE;

EID: 84938117616     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12666     Document Type: Article

References (45)

1. He, M. et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat. Genet. 45, 109-113 (2013).
2. Kelly, C. P. & LaMont, J. T. Clostridium difficile-more difficult than ever. New Engl. J. Med. 359, 1932-1940 (2008).
3. Barbut, F. et al. Prospective study of Clostridium difficile-associated disease in Europe with phenotypic and genotypic characterization of the isolates. Clin. Microbiol. Infect. 13, 1048-1057 (2007).
4. Kuijper, E. J. et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe. Eurosurveil. 13, e18942 (2008).
5. Freeman, J. et al. The Changing Epidemiology of Clostridium difficile Infections. Clin. Microbiol. Rev. 23, 529-549 (2010).
6. Fekety, R. et al. Epidemiology of antibiotic-associated colitis: isolation of Clostridium difficile from the hospital environment. Am. J. Med. 70, 906-908 (1981).
7. Gerding, D. N., Muto, C. A. & Owens, R. C. Measures to Control and Prevent Clostridium difficile Infection. Clin. Infect. Dis. 46, S43-S49 (2008).
8. Merrigan, M. et al. Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production. J. Bacteriol. 192, 4904-4911 (2010).
9. Marsh, J. W. et al. Association of Relapse of Clostridium difficile Disease with BI/NAP1/027. J. Clin. Microbiol. 50, 4078-4082 (2012).
10. Burns, D. A., Heeg, D., Cartman, S. T. & Minton, N. P. Reconsidering the Sporulation Characteristics of Hypervirulent Clostridium difficile BI/NAP1/027. PLoS ONE 6, e24894 (2011).
11. Paredes-Sabja, D., Shen, A. & Sorg, J. A. Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol. 22, 406-16 (2014).
12. Sorg, J. A. & Sonenshein, A. L. Bile salts and glycine as co-germinants for Clostridium difficile spores. J. Bacteriol. 190, 2505-2512 (2008).
13. Voth, D. & Ballard, J. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18, 247-263 (2005).
14. Pépin, J. et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Canad. Med. Assoc. J. 171, 466-472 (2004).
15. Hubert, B. et al. A Portrait of the Geographic Dissemination of the Clostridium difficile North American Pulsed-Field Type 1 Strain and the Epidemiology of C. difficile-Associated Disease in Québec. Clin. Infect. Dis. 44, 238-244 (2007).
16. Warny, M. et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. The Lancet 366, 1079-1084 (2005).
17. Vohra, P. & Poxton, I. Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile. Microbiol. 157, 1343-1353 (2011).
18. Lanis, J., Barua, S. & Ballard, J. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Path. 6, e1001061 (2010).
19. Morgan, O. W. et al. Clinical Severity of Clostridium difficile PCR Ribotype 027: A Case-Case Study. PLoS ONE 3, e1812 (2008).
20. Sirard, S., Valiquette, L. & Fortier, L.-C. Lack of Association between Clinical Outcome of Clostridium difficile Infections, Strain Type, and Virulence-Associated Phenotypes. J. Clin. Microbiol. 49, 4040-4046 (2011).
21. Robinson, C. D., Auchtung, J. M., Collins, J. & Britton, R. Epidemic Clostridium difficile strains demonstrate increased competitive fitness over non-epidemic isolates. Infect. Immun. 82, 2815-25 (2014).
22. Starr, J. M. & Campbell, A. Mathematical modeling of Clostridium difficile infection. Clin. Microbiol. Infect. 7, 432-437 (2001).
23. Starr, J. M., Campbell, A., Renshaw, E., Poxton, I. R. & Gibson, G. J. Spatio-temporal stochastic modelling of Clostridium difficile. J. Hosp. Infect. 71, 49-56 (2009).
24. Rubin, M. A. et al. A Simulation-Based Assessment of Strategies to Control Clostridium Difficile Transmission and Infection. PLoS ONE 8, e80671 (2013).
25. Codella, J., Safdar, N., Heffernan, R. & Alagoz, O. An Agent-based Simulation Model for Clostridium difficile Infection Control. Med. Dec. Making 35, 211-29 (2015).
26. Lanzas, C. & Dubberke, D. Effectiveness of screening hospital admissions to detect asymptomatic carriers of Clostridium difficile: a modeling evaluation. Infect. Control Hosp. Epidemiol. 35, 1043-1050 (2014).
27. Lanzas, C., Dubberke, E. Lu, Z., Reske, K. & Gröhn, Y. Epidemiological Model for Clostridium difficile Transmission in Healthcare Settings. Infect. Control Hosp. Epidemiol. 32, 553-561 (2011).
28. Yakob, L., Riley, T., Paterson, D. & Clements, A. Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC Infect. Dis. 13, 376 (2013).
29. Yakob, L., Riley, T. V., Paterson, D. L., Marquess, J. & Clements, A. C. A. Assessing control bundles for Clostridium difficile: a review and mathematical model. Emerg Microbes Infect 3, e43; doi: 10.1038/emi.2014.43 (2014).
30. Walker, A. S. et al. Characterisation of Clostridium difficile Hospital Ward-Based Transmission Using Extensive Epidemiological Data and Molecular Typing. PLoS Med 9, e1001172 (2012).
31. Eyre, D. W. et al. Diverse Sources of C. difficile Infection Identified on Whole-Genome Sequencing. New Engl. J. Med. 369, 1195-1205 (2013).
32. Bignardi, G. E. & Settle, C. Different ribotypes in community-acquired Clostridium difficile. J. Hosp. Infect. 70, 96-98 (2008).
33. Kermack, W. O. & McKendrick, A. G. A Contribution to the Mathematical Theory of Epidemics. Proc. Roy. Soc. A 115, 700-721 (1927).
34. MacCannell, D. et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J. Clin. Microbiol. 44, 2147-2152 (2006).
35. Wilcox, M. H. et al. Changing Epidemiology of Clostridium difficile Infection Following the Introduction of a National Ribotyping-Based Surveillance Scheme in England. Clin. Infect. Dis. 55, 1056-1063 (2012).
36. Bauer, M. P. et al. Clostridium difficile infection in Europe: a hospital-based survey. The Lancet 377, 63-73 (2011).
37. O'Connor, J. R., Johnson, S. & Gerding, D. N. Clostridium difficile Infection Caused by the Epidemic BI/NAP1/027 Strain. Gastroenterol. 136, 1913-1924 (2009).
38. Otete, E. H. et al. Parameters for the Mathematical Modelling of Clostridium difficile Acquisition and Transmission: A Systematic Review. PLoS ONE 8, e84224 (2013).
39. Keeling, M. & Rohani, P. Modeling infectious diseases in humans and animals. (Princeton University Press, 2008).
40. Loo, V. G. et al. Host and Pathogen Factors for Clostridium difficile Infection and Colonization. New Engl. J. Med. 365, 1693-1703 (2011).
41. Rafii, F., Sutherland, J. B. & Cerniglia, C. E. Effects of treatment with antimicrobial agents on the human colonic microflora. Therap. Clin. Risk Manag. 4, 1343-1358 (2008).
42. Bartlett, J. G. Treatment of antibiotic-associated pseudomembranous colitis. Rev. Infect. Dis. 6, S235-S241 (1984).
43. CDC. Frequently Asked Questions about Clostridium difficile for Healthcare Providers. < http://www.cdc.gov/hai/organisms/cdiff/cdiff-faqs-hcp.html> (2010) (Date of access:31/10/2014).
44. McFarland, L. V. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 5, 40-48 (2008).
45. Leffler, D. A. & Lamont, J. T. Treatment of Clostridium difficile-Associated Disease. Gastroenterol. 136, 1899-1912 (2009).